← Back to Search

Virus Therapy

HS135 for Pulmonary Arterial Hypertension

Phase 1
Waitlist Available
Research Sponsored by 35Pharma Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of WHO PAH Group 1
Body weight between 45 and 120 kg
Must not have
History of restrictive, constrictive or congestive cardiomyopathy
Uncontrolled systemic hypertension
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 weeks
Awards & highlights

Summary

This trial is testing a new drug called HS135 to see if it can help adults with a condition called pulmonary arterial hypertension.

Who is the study for?
Adults with Pulmonary Arterial Hypertension (PAH) who are on at least two PAH treatments can join. They must have a specific heart and lung function, weigh between 45-120 kg, and experience symptoms of PAH. Those with certain heart conditions, recent coronary events, uncontrolled high blood pressure or severe lung function impairment cannot participate.
What is being tested?
The trial is testing HS135 to see if it helps adults with Pulmonary Arterial Hypertension. Participants will receive HS135 while continuing their current PAH medications to determine the effectiveness and safety of this new treatment.
What are the potential side effects?
While the specific side effects of HS135 are not listed here, common side effects for PAH treatments may include headache, dizziness, nausea, diarrhea, swelling in ankles or feet and palpitations.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with pulmonary arterial hypertension.
Select...
My weight is between 45 and 120 kg.
Select...
I have symptoms of pulmonary arterial hypertension classified between mild to severe.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a history of heart muscle disease.
Select...
My high blood pressure is not under control.
Select...
I have had a procedure to create a hole in the wall between the upper chambers of my heart.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change from Baseline in Physical Examination

Trial Design

1Treatment groups
Experimental Treatment
Group I: HS135Experimental Treatment1 Intervention
Subcutaneous Injection

Find a Location

Who is running the clinical trial?

35Pharma IncLead Sponsor
1 Previous Clinical Trials
30 Total Patients Enrolled
Monique Champagne, M.Sc.Study DirectorVP Clinical Operations
~16 spots leftby Feb 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top